Clinical trials recruiting for EGFR Gene Mutation

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
  NCT07548060 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases
  NCT05033691 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
  NCT03175224 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
  NCT03042221 · Phase: Not specified · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
  NCT06643000 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
  NCT05598528 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
  NCT05503667 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
  NCT06071013 · Phase: Phase 1, Phase 2 · Ages: 20 Years to 70 Years · Sex: All (male and female) · 1 location
• Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.
  NCT06238882 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
  NCT04322890 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
  NCT06222489 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for EGFR Gene Mutation often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for EGFR Gene Mutation trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.